- Home
- PGP vs ATRA Comparison
PGP vs ATRA Comparison
Compare PGP & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGP
- ATRA
- Stock Information
- Founded
- PGP 2003
- ATRA 2012
- Country
- PGP United States
- ATRA United States
- Employees
- PGP N/A
- ATRA N/A
- Industry
- PGP Finance Companies
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PGP Finance
- ATRA Health Care
- Exchange
- PGP Nasdaq
- ATRA Nasdaq
- Market Cap
- PGP 97.1M
- ATRA 97.0M
- IPO Year
- PGP N/A
- ATRA 2014
- Fundamental
- Price
- PGP $8.61
- ATRA $14.41
- Analyst Decision
- PGP
- ATRA Strong Buy
- Analyst Count
- PGP 0
- ATRA 3
- Target Price
- PGP N/A
- ATRA $21.00
- AVG Volume (30 Days)
- PGP 39.8K
- ATRA 52.1K
- Earning Date
- PGP 01-01-0001
- ATRA 11-11-2025
- Dividend Yield
- PGP 10.84%
- ATRA N/A
- EPS Growth
- PGP N/A
- ATRA N/A
- EPS
- PGP N/A
- ATRA 0.56
- Revenue
- PGP N/A
- ATRA $188,667,000.00
- Revenue This Year
- PGP N/A
- ATRA N/A
- Revenue Next Year
- PGP N/A
- ATRA N/A
- P/E Ratio
- PGP N/A
- ATRA $25.58
- Revenue Growth
- PGP N/A
- ATRA 202.41
- 52 Week Low
- PGP $5.83
- ATRA $5.01
- 52 Week High
- PGP $7.81
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- PGP 59.39
- ATRA 68.37
- Support Level
- PGP $8.52
- ATRA $13.12
- Resistance Level
- PGP $8.62
- ATRA $14.78
- Average True Range (ATR)
- PGP 0.07
- ATRA 0.84
- MACD
- PGP -0.00
- ATRA 0.16
- Stochastic Oscillator
- PGP 76.92
- ATRA 86.14
About PGP Pimco Global StocksPlus & Income Fund of Beneficial Interest
PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).